Friday, June 22, 2018, Rockville, MD – Insilico Medicine, a Rockville-based company specializing in the application of artificial intelligence for drug discovery, biomarker development and aging research, announces the presentation of Verner De Biasi, Head of Digital Data and Analytics, PTS, GSK R&D, at the Artificial Intelligence and Blockchain in Healthcare Forum at the EMBO/Basel Life Conference.
Dr. De Biasi will co-chair the AI and Blockchain in Healthcare forum and give a talk titled "Leveraging the Blockchain from Bench to Bedside – How It Can Benefit the Patient" and devoted to the latest advances in the applications of Blockchain technology to patient care. The presentation will explore how Blockchain can enhance the relationships between healthcare providers and patients and enable patients to gain greater insights and benefits from it.
"Blockchain and Artificial Intelligence are immensely complimentary with each other, and now we are witnessing how both these technologies are enabling new, previously unthinkable applications in healthcare. I am happy to co-chair the AI and Blockchain for Healthcare innovation forum at the EMBO/Basel Life that gathers many thought leaders from the industry to expand the rising potential of AI and Blockchain for drug discovery and personalized management of life data in healthcare", said Verner De Biasi, Head Digital, Data and Analytics, PTS, GSK R&D.
Artificial Intelligence and Blockchain for Aging Research and Drug Discovery is turning into a credible industry and received recognition from the world's most prominent industry analysts including Frost & Sullivan and CB Insights.
2nd Artificial Intelligence and Blockchain in Healthcare innovation forum is an annual event at the EMBO/Basel Life Conference that brings together the key experts in AI and Blockchain to discuss the latest advances of these technologies in biopharmaceutical and healthcare sectors. This year the Forum is chaired by Alex Zhavoronkov, CEO at Insilico Medicine, and Verner De Biasi, Head Digital, Data and Analytics, PTS, GSK R&D, The event will be held in Basel on September 13-14, 2018.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. The paper published in Molecular Pharmaceutics in 2016 demonstrated the first proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients.
###
For further information, images or interviews, please contact:
Contact: Qingsong Zhu, PhD
[email protected]
Website: insilico.com
Official Forum Website: https://www.basellife.org/basel-life-2018/basel-life/innovation-forums/scientific-programme/artificial-intelligence-and-blockchain-in-healthcare.html
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered at in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions. The company and its scientists is dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com
Media Contact
Qingsong Zhu
[email protected]
410-710-9674
@InSilicoMeds
http://www.insilicomedicine.com
